PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $56,000 | – | 1,625 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 750,632 | $7,724,000 | 26.59% |
| BVF INC/IL | 2,617,967 | $26,939,000 | 2.37% |
| GREAT POINT PARTNERS LLC | 982,449 | $10,109,000 | 1.58% |
| Alambic Investment Management, L.P. | 65,128 | $670,000 | 0.53% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,243,202 | $23,083,000 | 0.14% |
| ALGERT GLOBAL LLC | 44,477 | $458,000 | 0.10% |
| Monashee Investment Management LLC | 42,945 | $442,000 | 0.09% |
| Tekla Capital Management LLC | 219,042 | $2,254,000 | 0.08% |
| Spark Investment Management LLC | 138,800 | $1,428,000 | 0.08% |
| OXFORD ASSET MANAGEMENT LLP | 187,653 | $1,904,000 | 0.04% |